Clinical Trial

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CD70-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CD70-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CD70-positive advanced malignancies were obtained and the recommended dose and infusion schedule.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-12.
Trial Details
NCT Number NCT07181720
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Conditions Renal Cell Carcinoma (RCC), Lung Cancer, Anaplastic Thyroid Carcinomas, Ovarian Cancer, Cervical Cancer, Thymic Carcinoma
Enrollment 90 participants
Start Date 2025-09-12
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-02